Arcturus Therapeutics (ARCT) News Today $16.02 -2.32 (-12.65%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by Sumitomo Mitsui Trust Group Inc.Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 45.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,275,715 shares of theNovember 16 at 4:49 AM | marketbeat.comArcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim DataNovember 14 at 2:02 PM | seekingalpha.comContrasting Arcturus Therapeutics (NASDAQ:ARCT) and Tharimmune (NASDAQ:THAR)November 14 at 3:01 AM | americanbankingnews.comMeiji Seika Pharma Announces Investment in ARCALIS, Inc.November 14 at 1:00 AM | businesswire.comArcturus Therapeutics: Overcoming Challenges and Poised for European ExpansionNovember 13, 2024 | markets.businessinsider.comArcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical TrialNovember 11, 2024 | businesswire.comArcturus Therapeutics: Strategic Growth and Robust Pipeline Justify Buy RatingNovember 11, 2024 | markets.businessinsider.comArcturus Therapeutics: Promising Future with Key Developments and Financial StabilityNovember 11, 2024 | markets.businessinsider.comHC Wainwright Has Positive Outlook of ARCT FY2028 EarningsArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Stock analysts at HC Wainwright raised their FY2028 earnings estimates for shares of Arcturus Therapeutics in a research note issued on Friday, November 8th. HC Wainwright analyst E. Arce now expects that the biotechnology companyNovember 11, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT)November 10, 2024 | americanbankingnews.comArcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats ExpectationsNovember 10, 2024 | finance.yahoo.comQ3 2024 Arcturus Therapeutics Holdings Inc Earnings CallNovember 8, 2024 | finance.yahoo.comArcturus Therapeutics: Strong Buy Rating Backed by Promising Kostaive Sales and Promising Pipeline DevelopmentsNovember 8, 2024 | markets.businessinsider.comArcturus Therapeutics Reports Q3 2024 Financial Results and MilestonesNovember 8, 2024 | markets.businessinsider.comArcturus Therapeutics' (ARCT) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Holdings Increased by ARK Investment Management LLCARK Investment Management LLC increased its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 6.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,101,038 shares of theNovember 8, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...November 8, 2024 | finance.yahoo.comArcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline ProgressNovember 8, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Buy" by BrokeragesArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has received an average rating of "Buy" from the eight brokerages that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buNovember 5, 2024 | marketbeat.comEmpire Life Investments Inc. Makes New $3.50 Million Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Empire Life Investments Inc. purchased a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 150,692 shares of the biotechnology company's stock, valued at approximatelyNovember 3, 2024 | marketbeat.comArcturus Therapeutics (ARCT) Set to Announce Quarterly Earnings on ThursdayArcturus Therapeutics (NASDAQ:ARCT) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average - Here's What HappenedArcturus Therapeutics (NASDAQ:ARCT) Stock Crosses Below Two Hundred Day Moving Average - Here's What HappenedNovember 1, 2024 | marketbeat.comIntellia Therapeutics: Assessing NTLA-2002’s Efficacy and Market Potential Amid Phase 2 Trial UpdatesOctober 25, 2024 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 6.1% - Should You Sell?Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.1% - Here's WhyOctober 24, 2024 | marketbeat.comInvesting in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gainOctober 24, 2024 | finance.yahoo.comA slow start for self-amplifying mRNA vaccinesOctober 23, 2024 | finance.yahoo.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 5.8% Following Insider SellingArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.8% Following Insider SellingOctober 17, 2024 | marketbeat.comPad Chivukula Sells 12,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) StockOctober 17, 2024 | insidertrades.comAQR Capital Management LLC Has $285,000 Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)AQR Capital Management LLC lessened its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 84.2% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 11,700 shares of the biotechnology company's stock after sellingOctober 17, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula Sells 12,000 SharesArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) COO Pad Chivukula sold 12,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the sale, the chief operating officer now owns 435,334 shares of the company's stock, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.October 16, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest UpdateArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 4,600,000 shares, a decline of 12.0% from the September 15th total of 5,230,000 shares. Based on an average daily trading volume, of 389,800 shares, the days-to-cover ratio is presently 11.8 days. Approximately 18.6% of the company's shares are short sold.October 14, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.9% - Time to Sell?Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 5.9% - Here's WhyOctober 10, 2024 | marketbeat.com29,499 Shares in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Bought by Squarepoint Ops LLCSquarepoint Ops LLC bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 29,499 shares of the biotechnology company's stock, valued at approximately $718,000.October 8, 2024 | marketbeat.comMillennium Management LLC Has $13.52 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Millennium Management LLC boosted its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 250.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 555,024 shares of the bioteOctober 7, 2024 | marketbeat.comArcturus shares hold with Buy rating on Japan vaccine progressOctober 4, 2024 | uk.investing.comPositive Outlook for Arcturus Therapeutics’ Vaccine Production and Distribution Spurs Buy RatingOctober 4, 2024 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.4% - Here's WhyArcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.4% - Here's WhyOctober 4, 2024 | marketbeat.comDimensional Fund Advisors LP Sells 185,598 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Dimensional Fund Advisors LP lessened its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 16.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 918,222 shares of the biotechnology comOctober 4, 2024 | marketbeat.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. reduced its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 27.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 244,154 shares of the biotechnology company'sOctober 2, 2024 | marketbeat.comBuy Rating Justified by Arcturus Therapeutics’ Market Potential and Strong Vaccine EfficacyOctober 2, 2024 | markets.businessinsider.comArcturus Therapeutics: A Strong Buy on Superior Vaccine Efficacy and Market PotentialOctober 1, 2024 | markets.businessinsider.comSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-VaccinationSeptember 30, 2024 | prnewswire.comAmerican Century Companies Inc. Sells 129,706 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)American Century Companies Inc. decreased its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 56.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 102,039 shares of the biotechnology company's stock after selling 129,7September 28, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Takes Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)Deerfield Management Company L.P. Series C acquired a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 39,328 shSeptember 27, 2024 | marketbeat.comXTX Topco Ltd Invests $596,000 in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)XTX Topco Ltd acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 24,481 shares of the biotechnology company's stock, valuedSeptember 24, 2024 | marketbeat.comArcturus Therapeutics (NASDAQ:ARCT) Trading 4.3% Higher Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 4.3%September 23, 2024 | marketbeat.comBuy Rating for Arcturus Therapeutics Amidst Promising mRNA Vaccine Developments for H5N1 InfluenzaSeptember 20, 2024 | markets.businessinsider.comArcturus Therapeutics (NASDAQ:ARCT) Shares Down 3.5% Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.5%September 18, 2024 | marketbeat.comArcturus Therapeutics: Strong Buy Rating on Vaccine Approval and Market Expansion ProspectsSeptember 18, 2024 | markets.businessinsider.com Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Strange: Why is Amazon suddenly yielding 39.70%? (Ad)Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%! Click here to see this breakthrough before everyone else → ARCT Media Mentions By Week ARCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARCT News Sentiment▼0.740.56▲Average Medical News Sentiment ARCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARCT Articles This Week▼134▲ARCT Articles Average Week Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revance Therapeutics News Stoke Therapeutics News Mersana Therapeutics News Shattuck Labs News Mirum Pharmaceuticals News Disc Medicine News Recursion Pharmaceuticals News Harmony Biosciences News Arvinas News Spyre Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARCT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts